The USD 75 million upfront payment removes near-term financing overhang. Monitor for TELLOMAK-3 enrollment updates and any potential accelerated approval filing timelines.
Price Chart
Executive Summary
Innate Pharma announces that its strategic partnership with Sobi for lacutamab is now effective, triggering a USD 75 million upfront payment. This resolves the near-term funding gap highlighted in the prior 20-F filing, extending cash runway and enabling the TELLOMAK-3 confirmatory Phase 3 study to begin.
Key Facts
- Partnership with Sobi for lacutamab in T-cell lymphoma is now effective after antitrust waiting periods expired.
- Transaction closing triggers a USD 75 million upfront payment to Innate Pharma.
- TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma to begin, first patient expected Q1 2027.
- Sobi receives exclusive global commercialization rights upon potential accelerated approval and may assume full global development rights after positive Phase 3 results.
Financial Impact
USD 75 million upfront payment received, significantly extending cash runway and addressing the going concern risk noted in the prior 20-F filing.
Risk Factors
- TELLOMAK-3 Phase 3 trial may fail to meet endpoints, delaying or preventing full approvals.
- Sobi's commercialization rights limit Innate's upside on future lacutamab sales.
- Cash runway still finite; additional financing may be needed before lacutamab generates revenue.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-062357 |
| Document: a6kseptember1620261.htm | 0001628280-26-062357 |
| Document: 0001628280-26-062357-index-headers.html | 0001628280-26-062357 |
| Document: 0001628280-26-062357-index.html | 0001628280-26-062357 |
| Document: 0001628280-26-062357.txt | 0001628280-26-062357 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $1.54 | awaiting T+20 | — | $1.49 (−3.25%) |
Oct 21, 2026 6d ago | 6-K | $1.57 | awaiting T+20 | — | $1.49 (−5.10%) |
Oct 20, 2026 7d ago | 6-K | $1.58 | awaiting T+20 | — | $1.49 (−5.58%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.49 (−21.99%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.49 (−21.99%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.49 (−21.99%) |
Sep 16, 2026 5w ago | Press Release | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.49 (−21.99%) |
Sep 10, 2026 6w ago | 6-K | $1.88 $1.48 | ▼ −21.28% | ▼ −23.40% | $1.49 (−20.74%) |
Sep 2, 2026 7w ago | 6-K | $2.17 $1.63 | ▼ −24.88% | ▼ −24.80% | $1.49 (−31.34%) |
Aug 14, 2026 10w ago | 6-K | $2.18 $1.85 | ▼ −15.14% | ▼ −13.15% | $1.49 (−31.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers